Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health has strengthened its focus on myopia research through an exclusive license agreement with BHVI for myopia control contact lenses. This partnership aims to develop lenses that may slow myopia progression in children, addressing a growing global health issue projected to affect 50% of the population by 2050. Earlier, Bausch + Lomb secured another licensing agreement with Eyenovia for a pediatric myopia treatment. CEO Joseph C. Papa emphasizes the commitment to innovative solutions for this increasing ocular disorder.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its gastroenterology division, Salix Pharmaceuticals, will present five scientific posters at the United European Gastroenterology (UEG) Week Virtual 2020 from Oct. 11-13, 2020. The presentations focus on innovative treatments addressing gastrointestinal diseases, specifically featuring studies on Rifaximin and Plecanatide related to conditions such as irritable bowel syndrome and chronic liver disease. Salix's commitment to research underscores its role as a leader in gastroenterology and aims to provide valuable insights for healthcare providers.

Bausch Health Companies Inc. (NYSE/TSX: BHC) provided a preliminary update on its third-quarter 2020 results, anticipating revenues exceeding $2.1 billion, a 28% sequential increase from Q2 2020. Despite this growth, revenue is expected to decline about 3% compared to Q3 2019. For the full year, the company estimates revenues between $7.80 and $8.00 billion, with Adjusted EBITDA expected between $3.15 and $3.30 billion.

Full financial results will be released on Nov. 3, 2020, along with a conference call.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that its Bausch + Lomb INFUSE™ silicone hydrogel daily disposable contact lenses will be featured in three poster presentations during the virtual American Academy of Optometry Annual Meeting from Oct. 7-22, 2020. The company has received positive feedback for the lenses since their launch in August, highlighting their comfort and performance. The research will cover various assessments, including the lens's dehydration resistance and its ability to mitigate contact lens dryness, aiming to enhance wearer experience.

Bausch Health Companies Inc. (BHC) announced the launch of LiverHEalthNow, an online resource aimed at improving the detection and management of Overt Hepatic Encephalopathy (OHE) in chronic liver disease patients. This initiative coincides with Liver Awareness Month and aims to educate healthcare providers and patients. Approximately 30 million Americans are affected by liver disease, with OHE being a severe complication. Salix Pharmaceuticals, part of Bausch Health, emphasizes the importance of early detection to improve patient outcomes and reduce hospital readmissions.

Bausch Health's LUMIFY® Eye Drops Honored in Nielsen's 2020 Top 25 Breakthrough Innovations

On October 1, 2020, Bausch Health Companies Inc. (BHC) announced that its LUMIFY redness reliever eye drops were recognized in the "Superstar" category by BASES, a Nielsen Global Consumer division, for outstanding sales and market growth. Launched in 2018, LUMIFY has secured a 40% market share among redness relievers and is the top recommended brand by eye doctors. This accolade highlights LUMIFY's effectiveness and innovative marketing, driving significant category growth and consumer engagement.

Bausch Health Companies Inc. announced that its ophthalmic solution, VYZULTA (latanoprostene bunod), has received regulatory approval in Ukraine, increasing its market reach to seven countries including the United States and Canada. In Canada, VYZULTA is now publicly reimbursed in multiple provinces. Moreover, Medicare Part D coverage in the U.S. rose to approximately 45% from 30%. The treatment is aimed at reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company aims to secure more approvals globally.

Bausch Health Companies released its 2019 Corporate Social Responsibility (CSR) Report, emphasizing its commitment to ethical and sustainable business practices. The report discusses the company's initiatives in five key areas: integrity, environmental respect, global health, community improvement, and employee well-being. Significant highlights include reductions in energy and carbon emissions, established an Energy Efficiency Group, and continued responsible pricing strategies with average annual price increases capped at single digits. The company also outlines its response to COVID-19 and ongoing diversity and inclusion efforts.

Bausch Health Companies Inc. (BHC) has resolved intellectual property disputes with Sun Pharmaceutical regarding XIFAXAN® (rifaximin) 200 mg and 550 mg tablets, maintaining market exclusivity until 2028. Under the agreement, Sun will receive a non-exclusive license to market generic versions effective January 1, 2028, pending FDA approval. The litigation will be dismissed, and all intellectual property for XIFAXAN remains intact, with 26 patents securing its market position. Final patent expirations are set for July and October 2029.